-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months to 17 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Michigan: Detroit
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Michigan: Rochester Hills
-
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Michigan: Ann Arbor, Detroit, East Lansing, Grand Rapids
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Michigan: Grand Rapids
-
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745 ·
Phase: Phase 1, Phase 2 ·
Ages: 2 Years to 12 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217 ·
Phase: Phase 3 ·
Ages: 2 Years to 55 Years ·
Sex: All (male and female)
· Michigan: Detroit
-
Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy
NCT07014592 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 75 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
NCT05374824 ·
Phase: Not specified ·
Ages: Up to 26 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
Diagnosing Epilepsy To EffeCT Change
NCT07110337 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Michigan: Farmington Hills
-
Functional Brain Mapping for Patients with Epilepsy
NCT05755919 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 6 Months to 21 Years ·
Sex: All (male and female)
· Michigan: Detroit
-
Goals for Epilepsy Clinic Visits Trial
NCT05928598 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
Outcomes After Planned Discontinuation of AntiSeizure Medication
NCT07750496 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Michigan: Ann Arbor
-
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
NCT05135091 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Michigan: Detroit